Type 1 diabetes screening moves from research to real-world care

Researchers are working to make blood testing for early-stage type 1 diabetes more accessible, helping families prepare sooner and reduce the risk of diagnosis in diabetic ketoacidosis.

Type 1 diabetes does not always announce itself with a crisis. In many cases, the immune attack that leads to the disease can be detected months or even years before a person needs insulin or develops obvious symptoms. Breakthrough T1D says that blood tests for type 1 diabetes-related autoantibodies can identify that earlier phase, giving families more time to understand what is happening and plan the next steps.

That window matters because earlier detection may help prevent diabetic ketoacidosis, a dangerous complication that can occur when type 1 diabetes is first discovered late. The US Centers for Disease Control and Prevention says screening can reveal early-stage disease before insulin is required, creating an opportunity for monitoring, preparation and, in some cases, participation in research studies or treatments designed to slow progression.

At the 2026 Breakthrough T1D Clinical & Research Congress, researchers and clinicians focused not just on whether screening works, but on how to make it practical. According to the organisation’s account of the meeting, participants discussed ways to make testing easier to complete at home or in community settings, while ensuring that people who screen positive receive clear explanations, follow-up and ongoing care. Dr Andrea Steck of the University of Colorado described how continuous glucose monitoring, combined with family history and autoantibody results, may help estimate how close someone is to developing stage 3 type 1 diabetes, while Dr Richard Oram of the University of Exeter discussed the possible role of DNA-based genetic risk scores in identifying people who could benefit from more detailed testing.

The research base behind this approach has been growing. A JAMA Network study of the Fr1da project in Bavaria found that screening in the general population could identify early-stage type 1 diabetes in children and that 36.2% progressed to clinical diabetes within five years. A review in the Journal of Paediatrics and Child Health also said type 1 diabetes moves through silent stages before the onset of overt hyperglycaemia, reinforcing the case for earlier identification and structured monitoring. In Canada, that work is still developing, but CanScreen T1D, or Canadian Population Screening for Risk of Type 1 Diabetes, is bringing researchers together to test how newborn and childhood screening could work nationally, including how results, monitoring and follow-up would be handled.